Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | clovisoncology.com | |
Description | Cancer In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer.We seek to develop targeted therapies to |
Keywords | N/A |
WebSite | clovisoncology.com |
Host IP | 104.130.135.23 |
Location | United States |
Site | Rank |
US$46,952,242
Last updated: 2023-05-01 02:04:34
clovisoncology.com has Semrush global rank of 225,427. clovisoncology.com has an estimated worth of US$ 46,952,242, based on its estimated Ads revenue. clovisoncology.com receives approximately 5,417,567 unique visitors each day. Its web server is located in United States, with IP address 104.130.135.23. According to SiteAdvisor, clovisoncology.com is safe to visit. |
Purchase/Sale Value | US$46,952,242 |
Daily Ads Revenue | US$43,341 |
Monthly Ads Revenue | US$1,300,216 |
Yearly Ads Revenue | US$15,602,592 |
Daily Unique Visitors | 361,172 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
clovisoncology.com. | A | 7199 | IP: 104.130.135.23 |
clovisoncology.com. | NS | 86400 | NS Record: ns5.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns3.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns6.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns2.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns7.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns4.markmonitor.com. |
clovisoncology.com. | NS | 86400 | NS Record: ns1.markmonitor.com. |
clovisoncology.com. | MX | 3600 | MX Record: 0 clovisoncology-com.mail.protection.outlook.com. |
clovisoncology.com. | TXT | 3600 | TXT Record: citrix-verification-code=81dcf6be-4a2b-4e23-a143-3267b9996959 |
clovisoncology.com. | TXT | 3600 | TXT Record: include:email.freshservice.com |
clovisoncology.com. | TXT | 3600 | TXT Record: docusign=258efdc6-19fa-4ed0-a93e-1391a23f72bb |
clovisoncology.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com include:sent-via.netsuite.com include:_spf.q4press.com include:psm.knowbe4.com ip4:23.23.239.161 ip4:74.84.203.40 ip4:74.84.203.38 ip4:135.84.68.123 ip4:3.228.204.181 -all |
clovisoncology.com. | TXT | 3600 | TXT Record: google-site-verification=gC5ioLL5rCbgqpZebNPBKZbliIvEI5MSXK77fGDTkYM |
clovisoncology.com. | TXT | 3600 | TXT Record: adobe-idp-site-verification=05ef518c-df4a-4e52-b456-50f0b15ce2c6 |
clovisoncology.com. | TXT | 3600 | TXT Record: docusign=b2fade49-5319-481c-8e70-1682e5afb223 |
clovisoncology.com. | TXT | 3600 | TXT Record: include:emailus.freshservice.com |
Contact Us Locations Menu About About Us Mission Leadership Transparency Reporting Products Pipeline Pipeline Overview Rucaparib FAP-2286 Lucitanib Scientific Presentations Clinical Trials Compassionate Use Patients Clinical Trials Patient Advocacy Patient Access Investors & News Bankruptcy Contact Us Locations Cancer Can’t keep me from living my life. Learn More Cancer Can’t outrun my research forever. Learn More Cancer Can’t keep us from finding solutions. Learn More Advancing the Fight Against Cancer In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer. We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient. Learn More Latest News Read More Read More JOIN US Help us develop cutting-edge treatments INVESTORS Investment information & stock performance Learn More EVENTS View our upcoming events and presentations Learn More |
HTTP/1.1 301 Moved Permanently Content-Length: 150 Content-Type: text/html; charset=UTF-8 ETag: " " Location: https://clovisoncology.com/ Server: Microsoft-IIS/8.5 Access-Control-Allow-Headers: Content-Type, SOAPAction Access-Control-Allow-Methods: GET, HEAD, POST Access-Control-Allow-Origin: * Referrer-Policy: strict-origin SameSite: none Strict-Transport-Security: max-age=10886400 X-Content-Type-Options: nosniff X-Frame-Options: sameorigin X-UA-Compatible: IE=edge,chrome=1 X-XSS-Protection: 1; mode=block Date: Sat, 23 Oct 2021 17:51:11 GMT HTTP/1.1 200 OK Cache-Control: private Content-Length: 26297 Content-Type: text/html; charset=utf-8 ETag: " " Access-Control-Allow-Headers: Content-Type, SOAPAction Access-Control-Allow-Methods: GET, HEAD, POST Access-Control-Allow-Origin: * Referrer-Policy: strict-origin SameSite: none Strict-Transport-Security: max-age=31536000; includeSubDomains; preload X-Content-Type-Options: nosniff X-Frame-Options: sameorigin X-UA-Compatible: IE=edge,chrome=1 X-XSS-Protection: 1; mode=block Date: Sat, 23 Oct 2021 17:51:11 GMT |
Domain Name: CLOVISONCOLOGY.COM Registry Domain ID: 1551638795_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2021-03-07T10:22:09Z Creation Date: 2009-04-08T14:42:32Z Registry Expiry Date: 2022-04-08T14:42:32Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS1.MARKMONITOR.COM Name Server: NS2.MARKMONITOR.COM Name Server: NS3.MARKMONITOR.COM Name Server: NS4.MARKMONITOR.COM Name Server: NS5.MARKMONITOR.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-12T03:54:43Z <<< |